Triple-Negative Breast Cancer | Topics

FDA Approves PD-L1 IHC 22C3 pharmDx as Companion Diagnostic for Pembrolizumab
November 16, 2020

The FDA approved the use of PD-L1 IHC 22C3 pharmDx as an aid in identifying patients with triple-negative breast cancer who may be appropriate for treatment with pembrolizumab (Keytruda).

Addition of Atezolizumab Improves pCR in Early TNBC, Irrespective of PD-L1 Status
September 20, 2020

Patients with triple-negative breast cancer experienced improved pathologic complete responses with the addition of neoadjuvant atezolizumab to chemotherapy.

PD-L1 Expression May Be Associated with Pathological Complete Response in TNBC
September 19, 2020

“PD-L1 expression was significantly associated with pCR, which increased with higher PD-L1 expression on immune cells,” said Giampaolo Bianchini, an author of the NeoTRIPaPDL1 study.